FILING ANALYSIS · THURSDAY, NOVEMBER 12
NEKTAR THERAPEUTICS NKTR — 8-K: Results of Operations and Financial Condition
neutral
Nektar Therapeutics reported a net loss of $55.7 million or $1.63 basic and diluted net loss per share for the third quarter of 2026, with revenue of $9.4 million and total operating costs and expenses of $67.2 million, and the company has $952.9 million in cash and investments in marketable securities as of September 30, 2026. The company initiated all three global ZENITH AD registrational trials
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →